A new trading day began on Monday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price down -2.38% from the previous day of trading, before settling in for the closing price of $4.62. RXRX’s price has ranged from $3.79 to $12.36 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -35.28% over the past five years. Meanwhile, its annual earnings per share averaged 7.17%. With a float of $332.88 million, this company’s outstanding shares have now reached $485.21 million.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 23.28%, while institutional ownership is 57.19%. The most recent insider transaction that took place on Nov 04 ’25, was worth 208,400. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $5.21, taking the stock ownership to the 974,229 shares. Before that another transaction happened on Nov 04 ’25, when Company’s Officer proposed sale 40,000 for $5.21, making the entire transaction worth $208,400.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.53 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.78% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 44.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.81, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 45.03 million, a positive change from its year-to-date volume of 29.87 million. As of the previous 9 days, the stock’s Stochastic %D was 13.17%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 11.00%, which indicates a significant decrease from 14.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.41 in the past 14 days, which was higher than the 0.39 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.27, while its 200-day Moving Average is $5.68. Nevertheless, the first resistance level for the watch stands at $4.82 in the near term. At $5.14, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.31. If the price goes on to break the first support level at $4.33, it is likely to go to the next support level at $4.16. Assuming the price breaks the second support level, the third support level stands at $3.84.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 1.96 billion, the company has a total of 434,152K Shares Outstanding. Currently, annual sales are 58,840 K while annual income is -463,660 K. The company’s previous quarter sales were 19,220 K while its latest quarter income was -171,900 K.
